Key Points – Azenta exceeded its third-quarter fiscal 2026 outlook, reporting $161 million in revenue, up 12% year over year and 9% organically.
Recurring-revenue businesses and improved Multiomics performance offset weakness in capital equipment, while adjusted EBITDA margin rose sharply sequentially to 11.4%. – Sample Management Solutions and Multiomics both delivered organic growth, but management cautioned that North American Multiomics improvement may reflect delayed project activity rather than a broad recovery
Europe and China remained stronger, while Automated Stores continued to face budget constraints and quality-related costs. – Azenta raised its fiscal 2026 revenue outlook to $613 million–$618 million and expects adjusted EBITDA of $59 million–$62 million. The company also repurchased $50 million of shares during the quarter and continues initiatives to standardize Automated Stores, reduce costs and improve scalability. – 5 medical stocks growing earnings by triple digits Azenta (NASDAQ:AZTA) reported third-quarter fiscal 2026 revenue that exceeded its outlook, as growth in recurring-revenue businesses and improved Multiomics performance helped offset continued unevenness in capital equipment markets. Total revenue was $161 million, up 12% on a reported basis and 9% organically from the prior-year period.
Both operating segments posted organic growth: Sample Management Solutions revenue rose 9% organically, while Multiomics increased 8% organically. Adjusted EBITDA margin was approximately 11.4%, down 60 basis points year over year but up 610 basis points sequentially. Non-GAAP earnings per share were $0.16.